28. Systemic amyloidosis
212 clinical trials,   234 drugs   (DrugBank: 72 drugs),   54 drug target genes,   170 drug target pathways

Searched query = "Systemic amyloidosis", "AL amyloidosis", "Immunoglobulin light chain amyloidosis", "Amyloid light-chain amyloidosis", "Familial amyloidosis", "Familial amyloid polyneuropathy", "Senile transthyretin amyloidosis", "Senile TTR amyloidosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2016-000276-23-GB
(EUCTR)
06/12/201611/07/2016Study to look at the affect of anti-SAP treatment in patients with cardiac amyloidosis A multiple treatment session, open label phase 2 clinical study of GSK2398852 administered following and together with GSK2315698 in cohorts of patients with cardiac amyloidosis Systemic amyloidosis
MedDRA version: 20.0;Level: SOC;Classification code 10021428;Term: Immune system disorders;System Organ Class: 10021428 - Immune system disorders
MedDRA version: 20.0;Level: PT;Classification code 10002022;Term: Amyloidosis;System Organ Class: 10021428 - Immune system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
GlaxoSmithKline Research & Development LtdNULLNot Recruiting Female: yes
Male: yes
30Phase 2United States;United Kingdom
2NCT01777243
(ClinicalTrials.gov)
May 13, 201324/1/2013A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic AmyloidosisA Single Dose First in Human Study of GSK2398852 Co-Administered With GSK2315698 in Patients With Systemic AmyloidosisAmyloidosisDrug: GSK2398852;Drug: GSK2315698GlaxoSmithKlineImperial College London;Heart Hospital;Royal Free Hospital NHS Foundation Trust;Quintiles, Inc.Completed18 Years70 YearsAll25Phase 1United Kingdom
3NCT01406314
(ClinicalTrials.gov)
October 13, 201126/7/2011SAP Depleter Dose Assessment Study in PatientsA Phase 1, Open Label, Dose Characteristic Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Intravenous and Subcutaneous Doses of GSK2315698A in Patients With Systemic AmyloidosisAmyloidosisDrug: GSK2315698GlaxoSmithKlineNULLCompleted18 Years80 YearsAll17Phase 1United Kingdom